



## 2020 Annual Meeting Program

Schedule (subject to change)

NOTE: all times are Eastern Daylight Time

### FRIDAY, JULY 24

6:00-6:05 PM

**Introduction**

**Timothy Murray, MD, MBA and Philip Ferrone, MD**

6:05-6:20 PM

**Retinal Cell Therapies Symposium**

Moderators: **Steven Becker, PhD; Russell Van Gelder, MD, PhD**

New Imaging Modalities for Monitoring Retinal Disease, **Steven Becker, PhD**

Barriers Facing Cell Replacement Therapies, **Russell Van Gelder, MD, PhD**

6:20-6:40 PM

**Technology Symposium: Updates in Artificial Intelligence (AI),  
Augmented Reality and Robotics**

Moderator: **Linda Lam, MD, MBA**

Multicenter, Head-to-Head, Real-World Validation Study of Artificial Intelligence Diabetic Retinopathy Screening Systems (AIDRSS), **Aaron Lee, MD, MSCI**

Augmented Reality Device Oculenz- Role in Improving Functional Vision in Patients With Age-Related Macular Degeneration, **Linda Lam, MD, MBA**

Translational Applications of Deep Learning in Retinopathy of Prematurity, **J. Peter Campbell, MD, MPH**

Time Independence, Optimized Surgical Steps - the Promise of Robotics, **Richard Rosen, MD, DSc(Hon)**

6:40-6:55 PM

**Imaging, Digital, Angiography Symposium 1**

Moderators: **John Pollack, MD; Caroline Bauml, MD**

Wide-Field Swept-Source Optical Coherence Tomography Angiography Versus Ultra-Wide Field Color Fundus Photo for Detecting Diabetic Retinopathy, **Dan Gong, MD**

Wide-Field Swept-Source Optical Coherence Tomography Angiography Versus Fluorescein Angiography for Detecting Diabetic Retinopathy, **John Miller, MD**

Swept-Source Optical Coherence Tomography Angiography Analysis of Intraretinal Microvascular Abnormalities, **Thomas Mendel, MD, PhD**

The Next Generation MIOCT System: Real Time Volumetric Intraoperative Optical Coherence Tomography With 4D Visualization of Surgical Maneuvers, **Lejla Vajzovic, MD**

6:55-7:10 PM

**Imaging, Digital, Angiography Symposium 2**

Moderators: **K. Bailey Freund, MD; Nadia Waheed, MD, MPH**

Swept Source OCT Angiography in Vitreomacular Traction - Natural Follow-up Versus Vitreoretinal Surgery, **Zofia Michalewska, MD, PhD**

Obstructive Sleep Apnea and Its Treatment Alter Choroidal Thickness in Patients With Central Serous Chorioretinopathy, **Carolyn Pan, MD**

Artificial Intelligence Algorithm May Improve Performance of Retinal Specialists in Detection of Retinal Fluid on OCT in AMD: AREDS2 10-Year Study, **Michael Elman, MD**

7:10-7:35 PM

**Retinal Vascular Disease Symposium**

Moderators: **Michael Ip, MD; James Major, Jr., MD, PhD FACS**

Deep Learning Detection of Sea Fan Neovascularization From Ultra-Widefield Fundus Images of Sickle Cell Hemoglobinopathy, **Sophie Cai, MD**

Real-World Treatment Patterns in Patients With Macular Edema Due to Retinal Vein Occlusion, **Vrinda Hershberger, MD, PhD**

Intravitreal Triamcinolone Acetonide in Advanced Coats' Disease Revisited: The Results of the King Khaled Eye Specialist Hospital, **Wael Alsakran, MD**

Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study, **J. Fernando Arevalo, MD, PhD, FACS**

Etiologic Profiling and Visual Outcomes of Dense Vitreous Hemorrhage Among Non-diabetics Treated With Pars Plana Vitrectomy, **Narciso Atienza, MD, MBA**

VEGF Blockage Prevents Healthy Retinal Regeneration - Noregen Promotes VEGF Modulation and Healthy In-Situ Retinal Regeneration in Vascular Disease, **Michael Trese, MD**

7:35-7:55 PM

**Inflammatory & Infectious Diseases Symposium**

Moderators: **Pauline Merrill, MD; Sunil Srivastava, MD**

Course of Macular Edema Through 36 Months With Fluocinolone Acetonide Intravitreal Insert for Non-infectious Uveitis Affecting the Posterior Segment, **Seenu Hariprasad, MD**

Intraocular Pressure Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension: Results From the Phase 3 PEACHTREE Clinical Trial, **Quan Nguyen, MD, MSc**

Outcomes of Infectious Endophthalmitis in Patients With Systemic Antibiotic Allergies or Cross Reactions to Intravitreal Vancomycin or Ceftazidime, **Prethy Rao, MD, MPH**

Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert, **Dilraj Grewal, MD**

7:55-8:10 PM

**Surgical Techniques and Maneuvers Symposium 1**

Moderators: **Young Hee Yoon, MD, PhD; Dean Elliott, MD**

Sutureless Intrasceral Fixation of Intraocular Lenses: Clinical Outcomes and Comparative Effectiveness of Haptic Flanging in a Series of 488 Eyes, **Ashkan Abbey, MD**

Visual Outcomes and Postoperative Complications of Pars Plana Vitrectomy for Dropped Nuclear Fragments: A Multicenter Database Study, **Ahmed Sallam, MD PhD FRCOphth**

A Microsurgical Vacuum Pick for Membrane Peeling Without Forceps, **Carl Awh, MD**

Amniotic Membrane Subretinal Transplantation to Promote Closure of Persistent Full-Thickness Macular Holes, **Jessica Lee, MD**

8:10-8:20 PM

**Surgical Techniques and Maneuvers Symposium 2**

Moderators: **Larry Halperin, MD; Sunir Garg, MD**

Presence of Neurofilament Light Chain (NfL) Proteins in the Vitreous Humor Can Serve as a Potential Ocular Biomarker for Neurodegeneration, **Manju Subramanian, MD**

Anterior Vitrectomy (AV) Versus Pars Plana Vitrectomy (PPV) in the Yamane Double Needle Technique: Refractive Outcomes and Complication Rates, **Rizwan Shaikh, MD**

Post Hoc Analysis of Clinical Suprachoroidal Injection Experience for Non-infectious Uveitis, **Shree Kurup, MD**

- 8:20-8:35 PM **ReST Committee Drug Safety Update**  
Paul Hahn, MD, PhD
- 8:35-8:40 PM **Poster Awards**  
Christina Weng, MD, MBA
- 8:40-8:45 PM **Film Festival Awards**  
Moderators: Theodore Leng, MD; Jonathan Chang, MD
- 8:45-8:55 PM **Business Meeting - Members Only**  
Timothy Murray, MD, MBA

## SATURDAY, JULY 25

- 10:00-10:25 AM **Diabetic Retinopathy Symposium 1**  
Moderators: Jeffrey Heier, MD; Gaurav Shah, MD
- Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T), **Dante Pieramici, MD**
- Complications, Compliance, and 2-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for PDR-Related Vitreous Hemorrhage, **Dennis Marcus, MD**
- Adjunctive Focal Laser Following Central Fluid Resolution After Bevacizumab, Ranibizumab, or Aflibercept Injection: A Secondary Analysis of Protocol T, **Jennifer Gallagher, MD**
- Intravitreal Aflibercept Injection for Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Study, **W. Lloyd Clark, MD**
- Incidence of New Diabetic Macular Edema in Fellow Eyes of Patients in the VISTA and VIVID Studies, **Sumit Sharma, MD**
- Severity of Diabetic Retinopathy as an Independent Risk Factor for Cerebral Vascular Accidents, Myocardial Infarctions, and All-Cause Mortality, **Bobek Modjtahedi, MD**
- 10:25-10:50 AM **Diabetic Retinopathy Symposium 2**  
Moderators: John Wells, MD, FACS; W. Lloyd Clark, MD
- Insights Into the Progression of Diabetic Retinopathy Severity Among Primary Care Patients With Diabetes in the United States, **Geeta Lalwani, MD**
- Artificial Intelligence Screening for Diabetic Retinopathy: Subgroup Comparison of the EyeArt System With Ophthalmologists' Dilated Exams, **Jennifer Lim, MD**

Current United States Treatment Patterns for the Treatment of Proliferative Diabetic Retinopathy in the IRIS Registry, **Jeremiah Brown, MD, MS**

Switching to Combination OPT-302 With Aflibercept From Prior Anti-VEGF-A Monotherapy in Eyes With Persistent Diabetic Macula Edema (DME), **David Boyer, MD**

Diabetic Retinopathy Progression in Anti-VEGF Versus Fluocinolone Acetonide Implant Treated Eyes Who Are Lost to Follow-up, **Caesar Luo, MD**

Progression to Proliferative Diabetic Retinopathy in Nonproliferative Diabetic Retinopathy Eyes Without Diabetic Macular Edema in the United States, **Ehsan Rahimy, MD**

10:50-11:10 AM

**Diabetic Retinopathy Symposium 3**

Moderators: **Susan Bressler, MD; Suber Huang, MD, MBA**

Intravitreal Liposome-Encapsulated Bromfenac for the Treatment of Refractory Diabetic Macular Edema, **Hugo Quiroz-Mercado, MD**

Longitudinal Panretinal Microaneurysm and Leakage Index Evaluation in Proliferative Diabetic Retinopathy in the RECOVERY Study: 2-Year Results, **Amy Babiuch, MD**

Baseline Diabetic Retinopathy Severity Affects Time to Clinically Meaningful Improvements in Diabetic Retinopathy During Ranibizumab Treatment, **Mitchell Goff, MD**

Treatment Effect of Intravitreal Aflibercept Injection by Baseline Factors in Moderately Severe-to-Severe NPDR in PANORAMA, **Nathan Steinle, MD**

Diabetic Retinal Telescreening Program in a High-Risk Population Highlights Significant Rates of Retinal Pathology, **Matthew Ohr, MD**

11:10-11:25 AM

**Socioeconomic/Practice Management Symposium 1**

Moderators: **Geoffrey Emerson, MD, PhD; Tushar Ranchod, MD**

Modifier-25 Examinations Reduce Travel Burden, Decrease Treatment Cost, and Improve QALY for Exudative Age-Related Macular Degeneration Patients, **Henry Leder, MD**

Cost of Initial Aflibercept, Laser, or Observation in Eyes With Diabetic Macular Edema and Good Vision Based on Management Approaches in Protocol V, **Jennifer Sun, MD**

Physician Quality Outcome Measures Don't Reliably Measure Quality for Individual Ophthalmologists, **John Thompson, MD**

11:25-11:35 AM

**Socioeconomic/Practice Management Symposium 2**

Moderators: **Jonathan Prenner, MD; Jonathan Jonisch, MD**

Medicare 2012-2017 Intravitreal Injections: Certification and Credentials of Providers, **Geoffrey Emerson, MD, PhD**

Opioid Prescribing Patterns and Trends of American Society of Retina Specialists (ASRS) Members, **Yoshihiro Yonekawa, MD**

Analysis of Emergent Non-Hospital Based Retina Consultation Requests in an Academic Non-Hospital Associated Retina Practice, **Barton Blackorby, MD**

11:35-11:40 AM

**Retina PractiCare 2.0 – Benchmarking Your Practice**

**John Thompson, MD**

11:40-11:55 AM

**Coding and Reimbursement Update**

Moderator: **Timothy Murray, MD, MBA**

Speakers: **Ankoor Shah, MD; John Thompson, MD; Christina Weng, MD, MBA**

11:55-12:05 PM

**Hereditary Retinal Diseases & Genetics Symposium**

Moderators: **Jason Comander, MD, PhD; Eric Nudleman, MD, PhD**

Intravitreal Injection of Allogeneic Human Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa: Results From the Phase 2b Trial, **Anthony Joseph, MD**

Genetic Profile and Associated Characteristics of 265 Korean Patients With Retinitis Pigmentosa, **Young Hee Yoon, MD, PhD**

Correlation Between Visual Function and Macular Morphological Characteristics Evaluated by SD-OCT in X-Linked Retinoschisis, **Honghua Yu, MD, PhD**

12:05-12:20 PM

**Pediatric Retina, ROP Symposium 1**

Moderators: **Audina Berrocal, MD; Sengul Ozdek, MD, FEBO**

Persistent Tunica Vasculosa Lentis as an Independent Risk Factor for Treatment in Retinopathy of Prematurity, **Nimesh Patel, MD**

Retinopathy of Prematurity Screening Using a Novel Method of Advanced Image Processing and Deep Machine Learning, **Omar Punjabi, MD**

Long-term Risk of Retinal Detachment in Pediatric Patients With Familial Exudative Vitreoretinopathy Previously Treated With Peripheral Laser, **Irina De la Huerta, MD PhD**

Results of Perimetry at Age of 10 Years in Severe ROP Eyes Receiving Laser or Anti-VEGF Treatment as Primary Monotherapy, **Alay Banker, MD**

12:20-12:35 PM

**Pediatric Retina, ROP Symposium 2**

Moderators: **Mary Elizabeth Hartnett, MD; Anna Ells, MD, FRCS(C)**

Efficacy of Aflibercept Treatment and Its Long-term Effect on Physiological Angiogenesis in a Mouse Model of Oxygen-Induced Retinopathy of Prematurity, **Andres Gonzalez, MD**

Laser Photocoagulation for Type 2 Retinopathy of Prematurity (ROP) or Less: When and Why?, **Edward Wood, MD**

Angiographic Review of Choroidal Involution in Eyes With Retinopathy of Prematurity Post-Bevacizumab Treatment, **Swati Agarwal-Sinha, MD**

Long-term Complications of Laser Treated Infants With Retinopathy of Prematurity, **Audina Berrocal, MD**

12:35-12:50 PM

**Surgical Techniques and Maneuvers Symposium 3**

Moderators: **Fabio Patelli, MD; Dante Pieramici, MD**

Creating Blebs for Subretinal Gene Delivery, **Andreas Lauer, MD**

Refractive Outcomes After Sutureless Intraclear Fixation of Secondary Intraocular Lens With Pars Plana Vitrectomy, **Ramon Lee, MD**

Macular Support for Posterior Staphyloma in High Myopia - Does Buckle Have a Beneficial Effect in Myopic Tractional Maculopathy?, **Pradeep Susvar, DNB, FRCS(Glasg), MBA**

Update on Paracentral Retinotomy for Resistant Macular Hole, **Michael Tsipursky, MD**

Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated With Vitreoretinal Surgery, **Daniel Kiernan, MD, FACS**

12:50-1:05 PM

**Surgical Techniques and Maneuvers Symposium 4**

Moderators: **Marco Mura, MD; Elliott Sohn, MD**

Intraoperative OCT Guided Vitrectomy for Optic Pit Maculopathy, **Makoto Inoue, MD**

Comparative Assessment of Conventional Microscope-Integrated to Digitally-Enabled Intraoperative OCT in Vitreoretinal Surgery in the DISCOVER Study, **Katherine Talcott, MD**

Comparative Study of Single Port Versus Dual Port Vitrectomy for the Treatment of Vitreous Opacities, **Luiz Lima, MD**

Visual Acuity Outcome in Patients With Subretinal Hemorrhage, Office Procedure Versus Surgical Treatment, **Rita Ehrlich, MD**

1:05-1:20 PM

**Surgical Techniques and Maneuvers Symposium 5**

Moderators: **Carl Regillo, MD; Ehab El-Rayes, MD, PhD**

Acute Intraoperative Hypotony During Automated Infusion Control,  
**Raymond Iezzi, MD, MS**

25-Gauge Pars Plana Vitrectomy in Eyes With Myopic Foveoschisis: A  
Long-term Follow-up Study, **Francesco Boscia, MD**

Real-World Visual Outcomes After YAG Vitreolysis for Vitreous Opacities  
(VOYAGE), **Netan Choudhry, MD, FRCS(C)**

Evaluation of the Intra-operative Efficiency of a Novel Hypersonic  
Vitrector in Typical Clinical Settings, **Victor Gonzalez, MD**

1:20-1:30 PM

**Ocular Oncology Symposium**

Moderators: **Prithvi Mruthjunyaya, MD, MHS; Tara McCannel, MD, PhD**

Complex Ocular Oncology: Evolving Treatments in the Absence of  
Clinical Trials - 3 Decades Focused on Decreasing Treatment Related  
Morbidity/Mortality, **Timothy Murray, MD, MBA**

Update From an Ongoing Phase 1b/2 Open-label Clinical Trial Evaluating  
the Safety and Efficacy of AU-011 for the Treatment of Choroidal  
Melanoma, **Ivana Kim, MD**

1:30-1:50 PM

**Retinal Detachment Symposium**

Moderators: **Tarek Hassan, MD; Kourous Rezaei, MD;**

Management of Proliferative Vitreoretinopathy With Intravitreal  
Methotrexate Using a Treat-and-Extend Protocol, **Scott Walter, MD, MSc**

Clinicopathologic Correlations of Retinal Membranes Associated With  
Intravitreal "Stem Cell" Injections, **Rehan Hussain, MD**

Outcomes of Sub-silicone Oil Triamcinolone Acetonide Application After  
3600 Relaxing Retinectomy for Complex Retinal Detachments – A  
Comparative Study, **Subhendu Boral, MBBS, MD(AIIMS),  
DNB(OPHTHALMOLOGY)**

Single Cell Genome-Wide Expression Profiling of Patient-Derived  
Membranes in Proliferative Vitreoretinopathy, **Leo Kim, MD, PhD**

Effect of Etiology on the Outcome in Pediatric Rhegmatogenous Retinal  
Detachment Undergoing Small Gauge Vitrectomy With Silicon Oil,  
**Navneet Mehrotra, DNB**

1:50-2:05 PM

**Macular Surgery Symposium 1**

Moderators: **Ivana Kim, MD; Mrinali Gupta, MD**

Multilayered Inverted Internal Limiting Membrane Flap - A Unique Technique for Closure of Large Macular Holes, **Srinivas Joshi, MD**

Spontaneous Conversion of Lamellar Macular Holes to Full-Thickness Macular Holes: Clinical Features and Surgical Outcomes, **Ismael Chehaibou, MD**

Clinical Characteristics, Risk Factors, and Surgical Outcomes of Secondary Macular Hole After Vitrectomy, **Min Kim, MD**

Pre-operative Predictive Factors for Post-operative External Limiting Membrane Restoration in Full-Thickness Macular Holes, **Ramachandran Nair, MBBS MS DO FRCS**

2:05-2:20 PM

**Macular Surgery Symposium 2**

Moderators: **Francesco Boscia, MD; Barbara Parolini, MD**

Comparison of the Embedding and Sparing Technique in Treating Lamellar Macular Holes With Lamellar Hole-Associated Epiretinal Proliferation, **Tso-Ting Lai, MD**

Relation of Anatomy With Function Following the Surgical Treatment of Idiopathic Epiretinal Membrane: A Multicentric Retrospective Study, **Sengul Ozdek, MD, FEBO**

Limited Vitrectomy for Epiretinal Membranes: A Comparative Multi-Center Trial, **Matteo Forlini, MD**

2:20-2:25 PM

**Closing Message**

**Philip Ferrone, MD**

**SUNDAY, JULY 26**

10:00-10:15 AM

**Dry AMD Symposium 1**

Moderators: **David Sarraf, MD; Sophie Bakri, MD**

Pentosan Polysulfate Maculopathy Versus Age-Related Macular Degeneration: Comparative Assessment With Multimodal Imaging, **Joseph Christiansen, MD**

Pentosan Polysulfate Maculopathy: Disease Course After Drug Cessation, **Rachel Shah, MD**

Phase 1 Safety Study of Intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a Novel Serine Protease Inhibitor, in Patients With GA, **William Bridges, MD**

Impact of Baseline OCT Characteristics on Response to Risuteganib for the Treatment of Intermediate Age-Related Macular Degeneration, **Justis Ehlers, MD**

10:15-10:30 AM

**Dry AMD Symposium 2**

Moderators: **Fernando Arevalo, MD, PhD, FACS; Arshad Khanani, MD**

Role of Metabolomics in Age-Related Macular Degeneration, **Deeba Husain, MD**

Nonneovascular Age-Related Macular Degeneration and Fluid, **David Sarraf, MD**

Genetic Susceptibility, Diet Quality and Drusen Size Progression: A Prospective Cohort Study, **Johanna Seddon, MD, ScM**

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD, **Baruch Kuppermann, MD, PhD**

10:30-10:50 AM

**Wet AMD Symposium 1**

Moderators: **Philip Ferrone, MD; David Brown, MD**

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD, **Peter Campochiaro, MD**

Intravitreal Gene Therapy for Neovascular AMD With ADVN-022: Results of the Phase 1 OPTIC Trial, **Charles Wykoff, MD, PhD**

Characteristics of Fellow Eye Conversion to Neovascular Age-Related Macular Degeneration in Patients With Unilateral Neovascular Disease, **Matthew Starr, MD**

High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis, **Jared Nielsen, MD, MBA**

Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?, **Marco Zarbin, MD, PhD**

10:50-11:10 AM

**Wet AMD Symposium 2**

Moderators: **Allen Ho, MD; Nathan Steinle, MD**

RGX-314 for Neovascular AMD: Ongoing Phase I/IIa Results for Cohorts 1-5, **Arshad Khanani, MD**

Comparative Efficacy of Different Anti-VEGF Treatment Regimens in Patients With nAMD: A Network Meta-Analysis, **Diana Do, MD**

Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial, **Gustavo Melo, MD, PhD**

Performance of a Novel Deep Learning Algorithm for Automatic Retinal Fluid Quantification in Home OCT Images, **Judy Kim, MD**

Number of Injections and Time to Dry Analysis of Brolocuzumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER, **Carl Regillo, MD**

11:10-11:25 AM

**Wet AMD Symposium 3**

Moderators: **Christina Weng, MD, MBA; Lisa Olmos de Koo, MD, MBA**

One-Year and Beyond: Results of Phase 1b Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO, **Mark Barakat, MD**

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results, **Peter Kertes, MD, FRCS(C)**

Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections, **Nancy Holekamp, MD**

Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs, **Michael Singer, MD**

11:25-11:35 AM

**Wet AMD Symposium 4**

Moderators: **Mark Humayun, MD, PhD; Diana Do, MD**

Morphological Changes in Polypoidal Lesions in Polypoidal Choroidal Vasculopathy, **Colin Tan, MBBS, MMed (Ophth), FRCSEd (Ophth)**

Loss to Follow-up in Patients With Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Therapy in the United States, **Rahul Khurana, MD**

Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD, **Rahul Komati, MD**

Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD), **David Brown, MD**

11:35-11:55 AM

**Wet AMD Symposium 5**

Moderators: **Baruch Kuppermann, MD, PhD; Leo Kim, MD, PhD**

Association Between CRT Fluctuation and BCVA With Abicipar Pegol Administered Every 12 Weeks for Neovascular AMD: CEDAR and SEQUOIA 52-Week Data, **Jeremy Wolfe, MD, MS**

Intravitreal AAVCAGsCD59 as Adjunct Anti-VEGF Treatment for Wet Age-Related Macular Degeneration (AMD), **Jeffrey Heier, MD**

Sustained Biweekly Aflibercept Improves Vision and Reduces Persistent Fluid in Refractory Neovascular AMD: Results From the Prospective TRISTAR Study, **Eric Schneider, MD**

Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results, **David Eichenbaum, MD**

Fluctuations in Central Foveal Thickness and Vision Outcomes With Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration, **Veeral Sheth, MD, MBA**

11:55-12:15 PM

**Wet AMD Symposium 6**

Moderators: **Peter Kaiser, MD; David Eichenbaum, MD**

Clinical Effects of Blocking Ang-2 and VEGF With Faricimab in the Phase 2 STAIRWAY Trial, **Carl Danzig, MD**

Peripheral Exudative Haemorrhagic Chorioretinopathy - A New Addition to the Spectrum of Pachychoroid Disease?, **Daraius Shroff, MS FMRF FRCS**

Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation, **Tarek Hassan, MD**

Effects of Ketoconazole on Clinical Recovery, Choroidal Thickness and Hormonal Profile in Patients With Central Serous Chorioretinopathy, **Yodpong Chantarasorn, MD**

Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway, **Dilsher Dhoot, MD**

12:15-12:35 PM

**Wet AMD Symposium 7**

Moderator: **Jay Duker, MD; Judy Kim, MD**

Predicting Long-term Response to Ranibizumab After Three Injections in Patients With Age-Related Macular Degeneration, **Paul Hahn, MD, PhD**

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Choroidal Neovascularization in AMD (ForeseeHome Device), **Allen Ho, MD**

Combination of Dexamethasone Implant and Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration, **Raja Narayanan, MD, MBA**

Ten-Year Follow-up of Patients With Exudative Age-Related Macular Degeneration Treated With Intravitreal Anti-VEGF Injections, **Sophie Bakri, MD**

Clinical Evaluation and PK/PD Modeling of the DARPIn Therapeutic Abicipar for the Treatment of Neovascular Age-Related Macular Degeneration, **Peter Kaiser, MD**

12:35-12:50 PM

**Instrumentation & Devices Symposium 1**

Moderators: **Carl Awh, MD; David Chow, MD, FRCS(C)**

The Effect of Latency on Digital Vitreoretinal Surgery, **David Tri Ta Kim, MD FRCS**

Cooling Anesthesia for Intravitreal Injection With a Novel Device: Results of the Prospective COOL-2 Study, **Daniel Chao, MD, PhD**

Microscope-Integrated Optical Coherence Tomography Can Measure the Volume of Subretinal Blebs Created by a Suprachoroidal Approach, **Ananth Sastry, MD**

Results From the Phase 3 PEACHTREE Clinical Trial: Systemic Therapy and the Efficacy of CLS-TA, a Post Hoc Analysis, **Ashvini Reddy, MD**

12:50-1:00 PM

**Instrumentation & Devices Symposium 2**

Moderators: **J. Michael Jumper, MD; Jorge Fortun, MD**

Lens and Peripheral Retinal Relationships During Vitrectomy: Comparison of 23, 25, and 27-Gauge Vitrectomy and Curved Endolaser Probes, **Jayanth Sridhar, MD**

Particulate Matter From Syringes Used for Intravitreal Injections, **Roger Goldberg, MD, MBA**

Post Hoc Analysis of Suprachoroidal Injection Experience Across Retinal Disease Indications, **Christopher Henry, MD**

1:00-1:15 PM

**Pediatric Take-Home Panel**

Moderator: **Darius Moshfeghi, MD**

Panelists: **Kimberly A. Drenser, MD; Jessica G. Lee, MD; Lejla Vajzovic, MD; Yoshihiro Yonekawa, MD**

1:15-1:30 PM

**Diabetic Retinopathy Take-Home Panel**

Moderator: **Charles Wykoff, MD, PhD**

Panelists: **Robert L. Avery, MD; Maria H. Berrocal, MD; Nancy M. Holekamp, MD; J. Michael Jumper, MD**

1:30-1:45 PM

**AMD Take-Home Panel**

Moderator: **David Boyer, MD**

Panelists: **Neil M. Bressler, MD; Margaret A. Chang, MD; Jennifer I. Lim, MD; Aleksandra V. Rachitskaya, MD**

1:45-1:50 PM

**Closing Message**

**Timothy Murray, MD, MBA; Philip Ferrone, MD**